BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rucaparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rucaparib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04253262-2060@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rucaparib: Phase 1/2 readout est. (NCT04253262)
DESCRIPTION:Rucaparib\, phase 1/2\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Copanlisib Combined With Rucaparib in Patient
 s With Metastatic Castration-resistant Prostate Cancer\nEstimated primary 
 completion: January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rucaparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04253262
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04455750-2060@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Rucaparib: Phase 3 readout est. (NCT04455750)
DESCRIPTION:Rucaparib\, phase 3\, Prostate Cancer.\nStudy: A Clinical Study
  Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With M
 etastatic Prostate Cancer That Has Become Resistant To Testosterone-Depriv
 ation Therapy\nEstimated primary completion: 15 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rucaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04455750
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2060@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rucaparib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Rucaparib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DRU
 P Trial)\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rucaparib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2060@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Rucaparib: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Rucaparib\, phase 3.\nStudy: A Study in Patients Previously Enr
 olled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizuma
 b Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rucaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2060@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Rucaparib: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Rucaparib\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimate
 d primary completion: 25 August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rucaparib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
